Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Neuron-Specific Genome Modification in the Adult Rat Brain Using CRISPR-Cas9 Transgenic Rats.

Bäck S, Necarsulmer J, Whitaker LR, Coke LM, Koivula P, Heathward EJ, Fortuno LV, Zhang Y, Yeh CG, Baldwin HA, Spencer MD, Mejias-Aponte CA, Pickel J, Hoffman AF, Spivak CE, Lupica CR, Underhill SM, Amara SG, Domanskyi A, Anttila JE, Airavaara M, Hope BT, Hamra FK, Richie CT, Harvey BK.

Neuron. 2019 Apr 3;102(1):105-119.e8. doi: 10.1016/j.neuron.2019.01.035. Epub 2019 Feb 18.

PMID:
30792150
2.

CYP3A5 Mediates Effects of Cocaine on Human Neocorticogenesis: Studies using an In Vitro 3D Self-Organized hPSC Model with a Single Cortex-Like Unit.

Lee CT, Chen J, Kindberg AA, Bendriem RM, Spivak CE, Williams MP, Richie CT, Handreck A, Mallon BS, Lupica CR, Lin DT, Harvey BK, Mash DC, Freed WJ.

Neuropsychopharmacology. 2017 Feb;42(3):774-784. doi: 10.1038/npp.2016.156. Epub 2016 Aug 18.

3.

Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry.

Hoffman AF, Spivak CE, Lupica CR.

ACS Chem Neurosci. 2016 Jun 15;7(6):700-9. doi: 10.1021/acschemneuro.5b00277. Epub 2016 Mar 28.

4.

Disruption of hippocampal synaptic transmission and long-term potentiation by psychoactive synthetic cannabinoid 'Spice' compounds: comparison with Δ9 -tetrahydrocannabinol.

Hoffman AF, Lycas MD, Kaczmarzyk JR, Spivak CE, Baumann MH, Lupica CR.

Addict Biol. 2017 Mar;22(2):390-399. doi: 10.1111/adb.12334. Epub 2016 Jan 5.

5.

An in vitro model of human neocortical development using pluripotent stem cells: cocaine-induced cytoarchitectural alterations.

Kindberg AA, Bendriem RM, Spivak CE, Chen J, Handreck A, Lupica CR, Liu J, Freed WJ, Lee CT.

Dis Model Mech. 2014 Dec;7(12):1397-405. doi: 10.1242/dmm.017251. Epub 2014 Oct 2.

6.

Blockade of β-cell K(ATP) channels by the endocannabinoid, 2-arachidonoylglycerol.

Spivak CE, Kim W, Liu QR, Lupica CR, Doyle ME.

Biochem Biophys Res Commun. 2012 Jun 22;423(1):13-8. doi: 10.1016/j.bbrc.2012.05.042. Epub 2012 May 15.

7.

A novel combination of factors, termed SPIE, which promotes dopaminergic neuron differentiation from human embryonic stem cells.

Vazin T, Becker KG, Chen J, Spivak CE, Lupica CR, Zhang Y, Worden L, Freed WJ.

PLoS One. 2009 Aug 12;4(8):e6606. doi: 10.1371/journal.pone.0006606.

8.

Dopaminergic neurons derived from BG01V2, a variant of human embryonic stem cell line BG01.

Vazin T, Chen J, Spivak CE, Amable R, Gabitzsch E, Lee CT, Lupica CR, Freed WJ.

Restor Neurol Neurosci. 2008;26(6):447-58.

9.

Discovery of (-)-7-methyl-2-exo-[3'-(6-[18F]fluoropyridin-2-yl)-5'-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties.

Gao Y, Kuwabara H, Spivak CE, Xiao Y, Kellar K, Ravert HT, Kumar A, Alexander M, Hilton J, Wong DF, Dannals RF, Horti AG.

J Med Chem. 2008 Aug 14;51(15):4751-64. doi: 10.1021/jm800323d. Epub 2008 Jul 8.

PMID:
18605717
10.

Gene expression profile of neuronal progenitor cells derived from hESCs: activation of chromosome 11p15.5 and comparison to human dopaminergic neurons.

Freed WJ, Chen J, Bäckman CM, Schwartz CM, Vazin T, Cai J, Spivak CE, Lupica CR, Rao MS, Zeng X.

PLoS One. 2008 Jan 9;3(1):e1422. doi: 10.1371/journal.pone.0001422.

11.

The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors.

Spivak CE, Lupica CR, Oz M.

Mol Pharmacol. 2007 Oct;72(4):1024-32. Epub 2007 Jul 12.

PMID:
17628012
13.

NTera2: a model system to study dopaminergic differentiation of human embryonic stem cells.

Schwartz CM, Spivak CE, Baker SC, McDaniel TK, Loring JF, Nguyen C, Chrest FJ, Wersto R, Arenas E, Zeng X, Freed WJ, Rao MS.

Stem Cells Dev. 2005 Oct;14(5):517-34.

PMID:
16305337
14.
16.

beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.

Spivak CE, Beglan CL, Zöllner C, Surratt CK.

Synapse. 2003 Jul;49(1):55-60.

PMID:
12710015
17.

Effects of extracellular sodium on mu-opioid receptors coupled to potassium channels coexpressed in Xenopus oocytes.

Oz M, Spivak CE.

Pflugers Arch. 2003 Mar;445(6):716-20. Epub 2003 Jan 18.

PMID:
12632192
18.

Direct noncompetitive inhibition of 5-HT(3) receptor-mediated responses by forskolin and steroids.

Oz M, Zhang L, Spivak CE.

Arch Biochem Biophys. 2002 Aug 15;404(2):293-301.

PMID:
12147268
19.
20.
21.

Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.

Spivak CE, Beglan CL, Seidleck BK, Hirshbein LD, Blaschak CJ, Uhl GR, Surratt CK.

Mol Pharmacol. 1997 Dec;52(6):983-92.

PMID:
9415708
22.
23.

Mutagenesis of the GABA rho 1 receptor alters agonist affinity and channel gating.

Kusama T, Wang JB, Spivak CE, Uhl GR.

Neuroreport. 1994 Jun 2;5(10):1209-12.

PMID:
7919166
25.

mu opiate receptor: cDNA cloning and expression.

Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR.

Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10230-4.

26.

Pharmacology of GABA rho 1 and GABA alpha/beta receptors expressed in Xenopus oocytes and COS cells.

Kusama T, Spivak CE, Whiting P, Dawson VL, Schaeffer JC, Uhl GR.

Br J Pharmacol. 1993 May;109(1):200-6.

27.

Behavioural and ligand-binding studies in rats with 1-acetyl-4-methylpiperazine, a novel nicotinic agonist.

Garcha HS, Thomas P, Spivak CE, Wonnacott S, Stolerman IP.

Psychopharmacology (Berl). 1993;110(3):347-54.

PMID:
7831430
28.

(+-)-Octahydro-2-methyl-trans-5 (1H)-isoquinolone methiodide: a probe that reveals a partial map of the nicotinic receptor's recognition site.

Spivak CE, Waters JA, Yadav JS, Shang WC, Hermsmeier M, Liang RF, Gund TM.

J Mol Graph. 1991 Jun;9(2):105-10, 100-1.

PMID:
1768639
29.

Electrophysiological and binding studies on intact NCB-20 cells suggest presence of a low affinity sigma receptor.

Wu XZ, Bell JA, Spivak CE, London ED, Su TP.

J Pharmacol Exp Ther. 1991 Apr;257(1):351-9.

PMID:
1850471
30.

Pharmacophore for nicotinic agonists.

Gund TM, Spivak CE.

Methods Enzymol. 1991;203:677-93. No abstract available.

PMID:
1762574
31.

Receptor binding and electrophysiological effects of dehydroepiandrosterone sulfate, an antagonist of the GABAA receptor.

Demirgören S, Majewska MD, Spivak CE, London ED.

Neuroscience. 1991;45(1):127-35.

PMID:
1661387
32.

The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor.

Majewska MD, Demirgören S, Spivak CE, London ED.

Brain Res. 1990 Aug 27;526(1):143-6.

PMID:
1964106
33.

Binding of semirigid nicotinic agonists to nicotinic and muscarinic receptors.

Spivak CE, Waters JA, Aronstam RS.

Mol Pharmacol. 1989 Jul;36(1):177-84.

PMID:
2747625
34.

Carbamyl analogues of potent nicotinic agonists: pharmacology and computer-assisted molecular modeling study.

Spivak CE, Yadav JS, Shang WC, Hermsmeier M, Gund TM.

J Med Chem. 1989 Feb;32(2):305-9.

PMID:
2913294
35.

Fractal models, Markov models, and channel kinetics.

McManus OB, Spivak CE, Blatz AL, Weiss DS, Magleby KL.

Biophys J. 1989 Feb;55(2):383-5. No abstract available.

36.

Fractal models are inadequate for the kinetics of four different ion channels.

McManus OB, Weiss DS, Spivak CE, Blatz AL, Magleby KL.

Biophys J. 1988 Nov;54(5):859-70.

37.

Synthesis, pharmacology, and molecular modeling studies of semirigid, nicotinic agonists.

Waters JA, Spivak CE, Hermsmeier M, Yadav JS, Liang RF, Gund TM.

J Med Chem. 1988 Mar;31(3):545-54.

PMID:
3258034
38.

Isoarecolone can inhibit nicotine binding and produce nicotine-like discriminative stimulus effects in rats.

Reavill C, Spivak CE, Stolerman IP, Waters JA.

Neuropharmacology. 1987 Jul;26(7A):789-92.

PMID:
3627386
39.

Structural and electronic requirements for potent agonists at a nicotinic receptor.

Spivak CE, Gund TM, Liang RF, Waters JA.

Eur J Pharmacol. 1986 Jan 14;120(1):127-31.

PMID:
3485051
40.

The activation of the nicotinic acetylcholine receptor by the transmitter.

Taylor DB, Spivak CE.

J Theor Biol. 1985 Feb 7;112(3):653-66.

PMID:
3982055
41.

Triphenylmethylphosphonium blocks the nicotinic acetylcholine receptor noncompetitively.

Spivak CE, Albuquerque EX.

Mol Pharmacol. 1985 Feb;27(2):246-55.

PMID:
2578604
42.
43.

Potencies and channel properties induced by semirigid agonists at frog nicotinic acetylcholine receptors.

Spivak CE, Waters J, Witkop B, Albuquerque EX.

Mol Pharmacol. 1983 Mar;23(2):337-43.

PMID:
6300643
44.

Actions of the histrionicotoxins at the ion channel of the nicotinic acetylcholine receptor and at the voltage-sensitive ion channels of muscle membranes.

Spivak CE, Maleque MA, Oliveira AC, Masukawa LM, Tokuyama T, Daly JW, Albuquerque EX.

Mol Pharmacol. 1982 Mar;21(2):351-61.

PMID:
6285171
45.

Ion exchange between agonists and inorganic ions at the acetylcholine receptor of Torpedo californica.

Spivak CE, Taylor DB.

Mol Pharmacol. 1980 Nov;18(3):413-20. No abstract available.

PMID:
7464806
46.

Anatoxin-a: a novel, potent agonist at the nicotinic receptor.

Spivak CE, Witkop B, Albuquerque EX.

Mol Pharmacol. 1980 Nov;18(3):384-94. No abstract available.

PMID:
6970328
47.

Mechanism of nicotinic channel activation and blockade.

Albuquerque EX, Adler M, Spivak CE, Aguayo L.

Ann N Y Acad Sci. 1980;358:204-38. No abstract available.

PMID:
6259990
48.

A filter assay for binding of labeled ligands to membrane-bound receptors.

Spivak CE, Taylor DB.

Anal Biochem. 1977 Jan;77(1):274-9. No abstract available.

PMID:
831577

Supplemental Content

Loading ...
Support Center